Get started
AUSTRALIAN CLINICAL LABS LIMITEDAUSTRALIAN CLINICAL LABS LIMITEDAUSTRALIAN CLINICAL LABS LIMITED

AUSTRALIAN CLINICAL LABS LIMITED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ACL chart


Full chart

ACL upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪702.02 M‬ AUD
Dividend yield (indicated)
3.43%
Price to earnings Ratio (TTM)
29.17
Basic EPS (TTM)
0.12 AUD
Net income (FY)
‪23.93 M‬ AUD
Revenue (FY)
‪689.73 M‬ AUD
Shares float
‪182.92 M‬
Beta (1Y)
0.81

Employees


Employees (FY)
‪4.9 K‬
Change (1Y)
−215 −4.20%
Revenue / Employee (1Y)
‪140.76 K‬ AUD
Net income / Employee (1Y)
‪4.88 K‬ AUD

About AUSTRALIAN CLINICAL LABS LIMITED


Sector
Health Services
Industry
Medical/Nursing Services
CEO
Melinda McGrath
Website
clinicallabs.com.au
Headquarters
Clayton
Founded
2020
ISIN
AU0000148496
FIGI
BBG0107G4386
Australian Clinical Labs Ltd. engages in the provision of pathology services. It operates through the Pathology segment. The Pathology segment includes pathology/clinical laboratory services provided in Australia. The company was founded in 2015 and is headquartered in Clayton, Australia.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ACL news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ACL is 3.53 AUD — it has increased by 0.86% in the past 24 hours. Watch AUSTRALIAN CLINICAL LABS LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange AUSTRALIAN CLINICAL LABS LIMITED stocks are traded under the ticker ACL.
ACL stock has risen by 2.32% compared to the previous week, the month change is a 0.28% rise, over the last year AUSTRALIAN CLINICAL LABS LIMITED has showed a 22.15% increase.
We've gathered analysts' opinions on AUSTRALIAN CLINICAL LABS LIMITED future price: according to them, ACL price has a max estimate of 3.90 AUD and a min estimate of 2.95 AUD. Watch ACL chart and read a more detailed AUSTRALIAN CLINICAL LABS LIMITED stock forecast: see what analysts think of AUSTRALIAN CLINICAL LABS LIMITED and suggest that you do with its stocks.
ACL reached its all-time high on Dec 29, 2021 with the price of 6.39 AUD, and its all-time low was 2.14 AUD and was reached on May 30, 2024. View more price dynamics on ACL chart.
See other stocks reaching their highest and lowest prices.
ACL stock is 2.59% volatile and has beta coefficient of 0.81. Track AUSTRALIAN CLINICAL LABS LIMITED stock price on the chart and check out the list of the most volatile stocks — is AUSTRALIAN CLINICAL LABS LIMITED there?
Today AUSTRALIAN CLINICAL LABS LIMITED has the market capitalization of ‪696.44 M‬, it has decreased by −3.89% over the last week.
Yes, you can track AUSTRALIAN CLINICAL LABS LIMITED financials in yearly and quarterly reports right on TradingView.
AUSTRALIAN CLINICAL LABS LIMITED is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
ACL earnings for the last half-year are 0.11 AUD per share, whereas the estimation was 0.08 AUD, resulting in a 33.75% surprise. The estimated earnings for the next half-year are 0.08 AUD per share. See more details about AUSTRALIAN CLINICAL LABS LIMITED earnings.
AUSTRALIAN CLINICAL LABS LIMITED revenue for the last half-year amounts to ‪359.10 M‬ AUD, despite the estimated figure of ‪340.00 M‬ AUD. In the next half-year revenue is expected to reach ‪361.70 M‬ AUD.
ACL net income for the last half-year is ‪18.98 M‬ AUD, while the previous report showed ‪4.95 M‬ AUD of net income which accounts for 283.32% change. Track more AUSTRALIAN CLINICAL LABS LIMITED financial stats to get the full picture.
AUSTRALIAN CLINICAL LABS LIMITED dividend yield was 4.78% in 2024, and payout ratio reached 99.75%. The year before the numbers were 4.07% and 78.21% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 30, 2024, the company has ‪4.90 K‬ employees. See our rating of the largest employees — is AUSTRALIAN CLINICAL LABS LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AUSTRALIAN CLINICAL LABS LIMITED EBITDA is ‪185.33 M‬ AUD, and current EBITDA margin is 26.87%. See more stats in AUSTRALIAN CLINICAL LABS LIMITED financial statements.
Like other stocks, ACL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AUSTRALIAN CLINICAL LABS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AUSTRALIAN CLINICAL LABS LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AUSTRALIAN CLINICAL LABS LIMITED stock shows the buy signal. See more of AUSTRALIAN CLINICAL LABS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.